Zimmer Biomet reported solid financial results for the fourth quarter and full year of 2024, with growth in both sales and earnings. Fourth quarter net sales reached $2.023 billion, a 4.3% increase (4.9% on a constant currency basis), driven by strong performance across key product lines. Diluted earnings per share (EPS) for the quarter were $1.20, while adjusted diluted EPS rose to $2.31, reflecting operational efficiency and effective cost management. For the full year, net sales grew 3.8% (4.8% on a constant currency basis) to $7.679 billion, with diluted EPS of $4.43 and adjusted diluted EPS of $8.00, demonstrating consistent growth and profitability.

Looking ahead, Zimmer Biomet provided financial guidance for 2025, signaling confidence in its ability to sustain growth and deliver value. The company’s performance in 2024 was supported by innovation, strategic investments, and a focus on improving operational efficiency. With a strong foundation and a clear growth strategy, Zimmer Biomet is well-positioned to continue its momentum in the medical technology sector.